What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and Xanthine derivatives at facilities including Tarapur in Maharashtra. Operates a CDMO/CMO business that recorded its highest-ever quarterly revenue of Rs. 155 crore in Q4 FY26. A new manufacturing block at Tarapur Unit 5 adds 3,600 TPA of Xanthine derivatives capacity, taking total Xanthine capacity to 9,600 TPA. Plans to begin R&D investment in peptides and oligonucleotides (TIDES) in FY27 and is building a dedicated CDMO block at Atali with a one-year completion target. Capex was approximately Rs. 400 crore in FY26, with similar levels guided for FY27. Materials make up 45.6% of revenue, the largest cost component, followed by other operating expenses at 24.3% and employee cost at 9.5%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from AARTI PHARMALABS LIMITED's filed financials and exchange disclosures
AARTI PHARMALABS LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol AARTIPHARM.
Yes. Over the trailing twelve months AARTI PHARMALABS LIMITED reported a net profit of ₹213 Cr on revenue of ₹1,969 Cr.
Yes. The dividend yield is 0.48% at the current price. It paid out 21% of its profit as dividend in FY26.
No. Debt stands at 0.32× equity, and it carries net debt of ₹677 Cr. That is lower than 29% of its 171 Pharmaceuticals peers.
On trailing P/E, AARTI PHARMALABS LIMITED ranks 98 of 169 in Pharmaceuticals — cheaper than 42% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session AARTI PHARMALABS LIMITED moves 1.46% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by AARTI PHARMALABS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
